Licorice exosomes and their application in preparing melanoma therapeutic drugs

Through the preparation of licorice exosomes and the method of wrapping STING signal agonists or coupling PD-L1 antibodies, the side effects and low response rates in melanoma treatment are solved, and licorice exosomes are realized in melanoma treatment The effective application of the disease significantly improved survival and tumor progression.

CN117987344BActive Publication Date: 2024-11-26深圳露泉生命产业有限公司
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311774475.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-12-21
Publication Date
2024-11-26
Estimated Expiration
2043-12-21

AI Technical Summary

Technical Problem

The existing melanoma treatment methods have high side effects, low response rate and limitations of immunotherapy, especially the limitation of animal-derived yield of exosomes and insufficient research on exosomes in traditional Chinese medicine plants.

Method used

Licorice exosomes are prepared by gradient centrifugation and membrane-filter extrusion technology, and licorice exosomes rich in specific miRNAs are prepared as a drug carrier, and STING signal agonist or coupled to PD-L1 Antibodies are used to promote T cells to kill tumor cells.

Benefits of technology

Licorice exosomes can inhibit melanoma cell proliferation and promote apoptosis in a concentration-dependent manner, enhance the killing effect of T cells on tumors, significantly improve the survival of mice and delay tumor progression, providing a new plant-derived exosome. Application in melanoma treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117987344B_ABST
    Figure CN117987344B_ABST
Patent Text Reader

Abstract

The present invention provides licorice exosomes and their use in preparing melanoma therapeutic drugs. The preparation method of the licorice exosomes comprises the following steps: washing and chopping licorice, preparing a homogenate and filtering, gradient centrifugation, resuspending, and extruding through a filter membrane. The licorice exosomes are rich in miRNAs such as Gma-miR6300, sly-miR9479-39, nta-miR6164a, bra-miR408-5p, and peu-miR2916. The licorice-derived exosomes can inhibit the proliferation of melanoma cells and promote their apoptosis. The licorice exosomes are further used as carriers to encapsulate STING signal agonists and couple anti-PDL1 antibodies, showing that licorice exosomes can cooperate with DMXAA and / or PDL1 antibodies to promote DC cell maturation and enhance the killing effect of T cells on tumors, effectively improving survival and delaying the progression of melanoma tumors.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and more specifically, to a licorice exosome and an application thereof in preparing a drug for treating melanoma. Background Art

[0002] Melanoma usually refers to malignant melanoma, which is the most deadly skin cancer. It originates from the malignant transformation and proliferation of melanocytes in the skin, mucous membranes, uvea, rectum and other parts. Due to the wide distribution of melanocytes, melanoma is ubiquitous regardless of the anatomical location or the type of organs and tissues. It is highly invasive, easy to metastasize, and has poor prognosis. Systemic treatment of malignant melanoma began with cytotoxic chemotherapy. In 1976, the first cytotoxic chemotherapy drug dacarbazine (DTIC) was approved in the United States for the treatment of metastatic malignant melanoma. On the one hand, dacarbazine has significant side effects such as bone marrow suppression, nausea and vomiting, and hepatotoxicity. On the other hand, the response rate of controlling the disease is less than 7.5%, and it is rarely used alone now.

[0003] The discovery of immune checkpoint inhibitors has revolutionized the treatment of metastatic and localized melanoma. PD-1 interacts with its ligands PD-L1 on tumor cells and antigen-presenting cells, and PD-L2 on activated monocytes and dendritic cells, inhibiting T cell activity and thereby regulating immune tolerance. Physiologically, the PD-1 / PD-L1 pathway is required as a regulatory checkpoint to slow down the degree of inflammation. Many tumors, especially melanoma, overexpress PD-L1 to produce an immunosuppressive tumor immune microenvironment. Blocking PD-1 or PD-L1 with antibodies can effectively promote anti-tumor immune responses to kill tumor cells.

[0004] The effectiveness of immunotherapy depends on the infiltration and activity of T cells in tumors, and innate immune agonists can promote the recruitment and killing of T cells by activating innate immunity. The cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) signaling pathway has been reported to promote DC cell maturation and release a variety of chemokines to promote the recruitment and activation of T cells, reshape the immunosuppressive microenvironment, and cooperate with PD-L1 antibodies to exert a good therapeutic effect. However, it can only be administered by intratumoral injection, which greatly limits its application prospects.

[0005] Exosomes are vesicles with a bimolecular phospholipid structure and a diameter of 30 to 150 nm. The surface contains a variety of bioactive substances such as DNA, RNA, protein, lipids, etc., which can transmit biological information over long distances, so they are called "natural drug carriers". However, animal-derived exosomes are limited in their production, which greatly limits their application. Plant-derived exosomes have a similar structure to animal exosomes. They are not only widely available, but also cheap and easy to mass produce and control. Plant-derived exosomes contain a variety of pharmacological molecules and miRNAs of natural products, which can be used not only as drug carriers but also as pharmacological substances. At present, there are few studies on plant exosomes related to traditional Chinese medicine, and the pharmacological mechanisms of some traditional Chinese medicine plant exosomes and their miRNAs are still unclear, so the study of traditional Chinese medicine plant exosomes and their miRNAs is also extremely important. Summary of the invention

[0006] The purpose of the present invention is to overcome the above-mentioned defects and deficiencies in the prior art and to provide a licorice exosome and its application in the preparation of a drug for treating melanoma.

[0007] The above-mentioned object of the present invention is achieved through the following technical solutions:

[0008] A method for preparing licorice exosomes comprises the following steps: washing and chopping licorice to prepare a homogenate and filtering it, separating it by gradient centrifugation, resuspending it, passing it through a 0.20-0.25 μm filter membrane and squeezing it out; the gradient centrifugation comprises centrifuging at 3500-4500 rpm for 18-22 min, centrifuging at 9500-15000 rpm for 35-45 min, and centrifuging at 35000-45000 g for 55-65 min, taking the supernatant and centrifuging it at 100000-200000 g for 80-100 min, and discarding the supernatant.

[0009] The present invention uses licorice as the extraction object. After pre-treating the licorice, it is first centrifuged at a low speed to remove impurities, and then centrifuged at a high speed to separate exosomes (i.e., gradient centrifugation), and then filtered through a membrane for extrusion; by controlling the speed and time of gradient centrifugation and the pore size of the filter membrane, licorice exosomes rich in miRNAs such as Gma-miR6300, sly-miR9479-39, nta-miR6164a, bra-miR408-5p, and peu-miR2916 can be prepared.

[0010] Furthermore, the homogenate is prepared by mixing licorice and water in a mass ratio of 1:8 to 12 and then crushing.

[0011] Preferably, the homogenate is prepared by mixing licorice and water in a mass ratio of 1:10 and then crushing.

[0012] Furthermore, the gradient centrifugation is carried out in sequence at 4000rpm-4500rpm for 20-22min, 10000-15000rpm for 40-45min, 40000-45000g for 60-65min, the supernatant is taken and centrifuged at 150000-200000g for 90-100min, and the supernatant is discarded.

[0013] Preferably, the gradient centrifugation is carried out in sequence at 4000 rpm for 20 min; 10000 rpm for 40 min; 40000 g for 60 min; the supernatant is obtained, centrifuged at 150000 g for 90 min, and the supernatant is discarded.

[0014] Furthermore, the membrane extrusion uses a 0.20-0.22 μm filter membrane.

[0015] Preferably, the membrane extrusion is performed using a 0.22 μm filter membrane.

[0016] Furthermore, the resuspension is performed using PBS.

[0017] The present invention also provides licorice exosomes prepared by any of the above-mentioned preparation methods. The present invention further observes the licorice exosomes by transmission electron microscopy, and finds that the morphology is a spherical shape with uniform texture. The particle size and potential of the licorice exosomes are measured by a Malvern particle size analyzer, proving that the particle size is uniform and stable.

[0018] The present invention also provides the use of any of the above-mentioned licorice exosomes as a drug carrier in the preparation of a licorice exocrine drug-carrying product.

[0019] The present invention also provides a licorice exosome drug-carrying product, which uses any of the above-mentioned licorice exosomes as a drug carrier to encapsulate a STING signal agonist and / or a coupled PD-L1 antibody.

[0020] Furthermore, the STING signaling agonist is DMXAA.

[0021] Furthermore, the PD-L1 antibody is coupled to the surface of licorice exosomes via DSPE-PEG-NHS.

[0022] Preferably, the licorice exosome drug-loaded product comprises the following combinations: licorice exosomes encapsulating the STING signal agonist DMXAA (licorice exosomes @DMXAA), licorice exosomes coupled to PD-L1 antibodies (licorice exosomes-aPDL1), and licorice exosomes encapsulating the STING signal agonist DMXAA and coupled to PD-L1 antibodies (licorice exosomes @DMXAA-aPDL1).

[0023] Furthermore, the method for preparing the liquorice exosome drug-carrying product comprises the following steps:

[0024] (1) Licorice exosomes encapsulating DMXAA: Take licorice exosomes and DMXAA, and gently mix them in the electroporation solution at 4°C. Use a Bio-Rad electroporator and a 0.4 cm electroporation cup for electroporation. After electroporation, let it stand on ice for 30 minutes and perform membrane complexation. Repeat the electroporation and membrane complexation operations once. Filter through a 100 kDa ultrafiltration tube at 4000 r×15 min, remove the filtrate, and repeat this operation once to remove the unencapsulated DMXAA.

[0025] (2) Licorice exosomes conjugated with PD-L1 antibody: PDL1 antibody: DSPE-PEG-NHS were mixed at a molar ratio of 1:5 and shaken at 4°C overnight. Licorice exosomes were mixed with antibodies linked to DSPE-PEG-NHS, gently mixed, kept in a refrigerator at 4°C overnight, and filtered through a 100 kDa ultrafiltration tube at 4000 r×15 min, the filtrate was removed, and the operation was repeated once to remove unlinked antibodies.

[0026] Preferably, the electrotransfer solution comprises 1.15 mM potassium hydrogen phosphate at pH 7.2 and 21% 25 mM potassium chloride.

[0027] Preferably, the electroconversion conditions are 300V, 150μF.

[0028] The present invention has been proved by CFSE detection and cell apoptosis kit detection that licorice exosomes can promote melanoma cell apoptosis and inhibit melanoma cell proliferation in a concentration-dependent manner. The miRNA of licorice exosomes was extracted by a kit, and functional enrichment and further tumor killing mechanism research were carried out. It was found that the miRNA with the highest abundance in the licorice exosomes was Gma-miR6300, sly-miR9479-39, nta-miR6164a, bra-miR408-5p, and peu-miR2916. Among them, the proliferation and vitality of melanoma cells after miRNA-2916 transfection were significantly inhibited. This study suggests that licorice exosomes can not only be used as drug carriers, but also as pharmacological substances in the prepared drug system. Furthermore, by encapsulating the STING signal agonist DMXAA and coupling it with anti-PDL1 antibodies, DC cell maturation can be promoted and the killing effect of T cells on tumors can be enhanced. The constructed drug system was further applied to the subcutaneous melanoma model of mice, which significantly enhanced the killing of tumor-infiltrating T cells, effectively improved the survival of mice and delayed tumor progression. It can be seen that the licorice exosomes of the present invention and the drugs they carry (licorice exosomes @DMXAA, licorice exosomes-aPDL1, licorice exosomes @DMXAA-aPDL1) form a synergistic effect in the treatment of melanoma.

[0029] Therefore, the present invention provides the use of any of the above-mentioned licorice exosomes or any of the above-mentioned licorice exosome drug-loaded products in the preparation of tumor therapeutic drugs.

[0030] Furthermore, the tumor is melanoma.

[0031] The present invention also provides the use of miRNA-2916 in preparing a drug for treating melanoma. The miRNA-2916 sequence is uggggacucgaagacgaucauau.

[0032] Compared with the prior art, the present invention has the following beneficial effects:

[0033] The present invention provides a licorice exosome as a new plant-derived exosome, which is rich in miRNAs such as Gma-miR6300, sly-miR9479-39, nta-miR6164a, bra-miR408-5p, and peu-miR2916. The licorice-derived exosomes can inhibit the proliferation of melanoma cells and promote their apoptosis. The licorice exosomes are further used as carriers to encapsulate STING signal agonists and couple them with anti-PDL1 antibodies, showing that licorice exosomes can cooperate with DMXAA and / or PDL1 antibodies to promote DC cell maturation and enhance the killing effect of T cells on tumors, effectively improving survival and delaying the progression of melanoma tumors. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Figure 1 Characterization of exosomes derived from licorice. A is the particle size distribution of licorice exosomes; B is the Zeta potential of licorice exosomes; C is the morphology of licorice exosomes detected by transmission electron microscopy, Bar = 500nm; D is the endocytosis of licorice exosomes into melanoma cell line B16F10, Bar = 10μm.

[0035] Figure 2 This is a study on the mechanism of anti-melanoma effect of licorice-derived exosomes. A is the fluorescence intensity of B16F10 cells 48 hours after adding licorice exosomes after CFSE staining; B is the statistical analysis of CFSE fluorescence intensity; C is the apoptosis of B16F10 cells 48 hours after adding licorice exosomes; D is the statistical analysis of apoptosis.

[0036] Figure 3This is a study on miRNA in licorice exosomes. A is the intersection of miRNAs found after three repeated experiments; B is the GO analysis of miRNAs in the intersection; C is the KEGG analysis of miRNAs in the intersection; D is the 5 most abundant miRNAs in the intersection of miRNAs; E is B16F10 cells transfected with miRNA-2916, cultured for 48 hours, the culture medium was aspirated, 90μL PBS buffer and 10μL cck8 reagent were added, and the absorbance at 460nm was measured after incubation at 37 degrees in the dark for 2 hours.

[0037] Figure 4 The licorice exosomes encapsulate DMXAA and couple with PDL1 antibody and their effects on DC cells and T cells. A is the detection of DMXAA encapsulation efficiency; B is the detection of antibody linking efficiency; C is the detection of T cell killing tumor cell ability; D is the statistical chart of T cell killing tumor cell ability; E is the detection of DC cell maturation; F is the statistical chart of DC cell maturation.

[0038] Figure 5 The in vivo targeting and anticancer effects of licorice exosomes encapsulating DMXAA and conjugating PDL1 antibodies. A is a live imaging image; B is a photo of mouse tumors after 5 treatments; C is a mouse tumor volume curve. D is a mouse weight curve; E is a mouse survival curve; F is a flow cytometer analysis of mouse tumor tissue obtained after 5 treatments; G is a flow analysis statistical chart. DETAILED DESCRIPTION

[0039] The present invention is further described below in conjunction with the accompanying drawings and specific examples, but the examples do not limit the present invention in any form. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art.

[0040] Unless otherwise specified, the reagents and materials used in the following examples are commercially available.

[0041] Example 1 Preparation and characterization of licorice exosomes

[0042] After washing and chopping the licorice, add it into a wall breaking machine at a licorice: water mass ratio of 1:10, and filter it after breaking it into a homogenate. Separate it by gradient centrifugation, i.e. 4000rpm×20min, 10000rpm×40min, 40000g×60min, take the supernatant for 150000g×90min, discard the supernatant, resuspend it in PBS and obtain it by membrane extrusion through a 0.22μm filter membrane.

[0043] The particle size and potential of licorice exosomes were measured by Malvern particle size analyzer. The particle size was around 128nm and the Zeta potential was -21mV, which proved that the particle size was uniform and stable. Figure 1 A, B). The morphology of exosomes was observed by transmission electron microscopy, and it was found that licorice exosomes were spherical structures with uniform texture ( Figure 1 C).

[0044] WGA488-stained licorice exosomes (150 μg / mL, protein amount) were added to the melanoma cell line B16F10 and incubated in a 37°C incubator for 1 hour. The supernatant was removed and washed twice with PBS. After fixation with 4% paraformaldehyde for 15 minutes, the cell nuclei were stained with DAPI (5 ug / mL) for 15 minutes, and then the endocytosis of licorice exosomes by B16F10 was detected using a confocal microscope. Bar = 10 μm. The results are shown in Figure 1 As shown in D, exosomes labeled with green fluorescence can be seen around the cell nucleus labeled with blue fluorescence, indicating that melanoma cells can internalize exosomes.

[0045] Example 2 Study on the mechanism of anti-melanoma effect of licorice exosomes

[0046] Melanoma cell line B16F10 cells were resuspended in PBS, CFSE dye (2uM) was added for staining at 37°C for 15 minutes, complete medium was added to terminate the staining, and PBS was washed twice. 2×10 5 B16F10 cells were seeded in 12-well plates and added with 0, 50, 100, 150, and 200 μg / mL of licorice exosomes (based on protein amount). After 48 hours, the cells were collected and washed with PBS and the fluorescence intensity was detected by flow cytometry. The fluorescence intensity of CFSE was statistically analyzed. The results are shown in Figure 2 As shown in A and B, licorice exosomes have the effect of inhibiting melanoma proliferation, and this effect is concentration-dependent.

[0047] 2×10 5 Melanoma cell line B16F10 cells were seeded in 12-well plates and added with 0, 50, 100, 150, and 200 μg / mL of licorice exosomes (based on protein amount). After 48 hours, the culture medium was collected and the adherent cells were digested with EDTA-free trypsin and washed with PBS. The cells were stained according to the instructions of the kit and apoptosis was detected by flow cytometry. The apoptosis was statistically analyzed. Figure 2 As shown in C and D, as the drug concentration increases, the proliferation ability of tumor cells is inhibited, and the proportion of cell apoptosis continues to increase. When the concentration reaches 150μg / mL, there is a relatively good inhibitory effect, so 150μg / mL concentration is selected as the concentration used in subsequent experiments.

[0048] In summary, CFSE detection and cell apoptosis kit detection proved that licorice exosomes can promote melanoma cell apoptosis and inhibit melanoma cell proliferation in a concentration-dependent manner.

[0049] Example 3 Identification of miRNA in Licorice Exosomes and Study of Its Tumor Killing Mechanism

[0050] The miRNA in licorice exosomes was extracted and sequenced using a kit method. The kit used was miRNA Library Kit, the experiment was repeated 3 times. Figure 3 A is the intersection of miRNAs found after repeating the experiment three times, with a total of 2084 intersection miRNAs. GO analysis was performed on the miRNAs in the intersection, and the results are as follows Figure 3 As shown in B, the enriched genes are related to mitochondrial function and intercellular signaling. KEGG analysis was performed on the miRNAs in the intersection, and the results are as follows Figure 3 As shown in Figure 3, the enriched pathways include cell proliferation signaling pathways such as the PI3K-AKT signaling pathway and the MAPK signaling pathway, which is consistent with the results of licorice exosomes inhibiting melanoma cell proliferation verified in Example 2. The five miRNAs with the highest abundance in the miRNA intersection are Gma-miR6300, sly-miR9479-39, nta-miR6164a, bra-miR408-5p, peu-miR2916( Figure 3 D).

[0051] The melanoma cell line B16F10 cells plated in a 96-well plate were transfected with miRNA-2916 mimics (purchased from Jima Gene). After 48 hours of incubation, the medium was aspirated, 90 μL PBS buffer and 10 μL cck8 reagent were added, and the absorbance at 460 nm was measured after incubation at 37 degrees in the dark for 2 hours. The results are shown in FIG. Figure 3 As shown in Figure E, the proliferation and vitality of melanoma cells after miRNA-2916 transfection were significantly inhibited, which suggests that miRNA in plant-derived exosomes can also be used as a pharmacological substance, that is, licorice exosomes can play a role as a pharmacological substance in the treatment of melanoma.

[0052] Example 4 Construction of Licorice Exosome Drug Delivery System and Its Effects on DC Cells and T Cells

[0053] Construction of DMXAA drug delivery system encapsulated by licorice exosomes: Take 0.5 mg of licorice exosomes and 200 μg of DMXAA, and gently mix them in the electrotransfer solution at 4°C. The components of the electrotransfer solution are 1.15 mM potassium hydrogen phosphate at pH 7.2 and 21% 25 mM potassium chloride. Use Bio-Rad electrotransfer instrument and 0.4 cm shock cup for electrotransformation. The electrotransformation conditions are 300 V and 150 μF. After electrotransformation, let it stand on ice for 30 minutes and perform membrane complexation. Repeat the electrotransformation and membrane complexation operations once. Filter through a 100 kDa ultrafiltration tube for 4000 r×15 min, remove the filtrate, and repeat the operation once to remove the unencapsulated DMXAA. The DMXAA stock solution was prepared at a concentration of 5 mg / mL, and was gradiently diluted to 0.5, 0.2, 0.1, 0.05, 0.01, and 0.001 mg / mL, and the concentration-absorbance standard curve at the maximum absorbance was determined by the UV method. The electroporated licorice exosomes were centrifuged to obtain the supernatant and the UV absorption value was determined. The encapsulation efficiency was calculated using the formula: drug encapsulation efficiency (%) (ER) = MR / MT × 100%; MR is the mass of DMXAA in the supernatant, and MT is the total mass of DMXAA in the sample. The DMXAA encapsulation efficiency is as follows: Figure 4 As shown in A.

[0054] Construction of licorice exosome-coupled PD-L1 antibody drug delivery system: PDL1 antibody and DSPE-PEG-NHS were mixed at a molar ratio of 1:5 for PDL1 antibody: DSPE-PEG-NHS, and shaken at 4°C overnight. 1 mg of licorice exosomes was mixed with 300 μg of antibody linked to DSPE-PEG-NHS, mixed gently, kept in a refrigerator at 4°C overnight, and filtered through a 100 kDa ultrafiltration tube at 4000 r×15 min, the filtrate was removed, and the operation was repeated once to remove unlinked antibodies, and FITC-mouse-igG1 flow cytometry antibody was added for staining on ice for 15 minutes, and then the fluorescence intensity of the nanoparticles was detected by nanoflow cytometry. The antibody linking efficiency is as follows Figure 4 As shown in B.

[0055] CD3 positive T cells were sorted from the spleen of 6-week-old male C57BL / 6 mice and cultured in a 37°C incubator for 3 days under the following culture conditions: glutamine 2mM; mCD3 3ug / mL; mCD28 3ug / mL; mIL-2 2ng / mL; 20% fetal bovine serum. B16F10 cells were resuspended in PBS and stained with CFSE dye (2uM) at 37°C for 15 minutes. Complete culture medium was added to terminate the staining and the cells were washed twice with PBS before plating. Licorice exosomes (150 μg / mL, in terms of protein) and licorice exosomes linked to PD-L1 antibodies (150 μg / mL, in terms of protein), i.e., licorice exosomes-aPDL1, were added to B16F10 cells. After incubation for 2 hours, T cells were added so that tumor cells: T cells = 1:5. After culturing in an incubator for 24 hours, the suspended cells were removed, the B16F10 cells were digested, and the CFSE fluorescence level was detected by flow cytometry. The ability of T cells to kill tumor cells and the statistical graphs are shown in the figure below. Figure 4 As shown in C and D, exosome-like cells can enhance the inhibitory effect of T cells on tumor cell proliferation, and exosome-like cells coupled with PD-L1 antibodies can significantly enhance the killing effect of T cells on tumors and inhibit tumor cell proliferation.

[0056] Bone marrow cells were extracted from 6-week-old male C57BL / 6 mice, and GM-CSF (20 ng / mL) and IL-4 (10 ng / mL) were added to 1640 medium containing 10% FBS to induce the formation of BMDC cells. That is, the suspended cells were centrifuged on the 3rd day, half of the medium was removed, and half of the medium containing GM-CSF and IL-4 was added. On the 5th day, the suspended cells were collected, all the medium was removed, and the cells were resuspended in 1640 medium containing GM-CSF and IL-4. On the 6th day, immature BMDC cells induced were obtained. In addition, B16F10 cells were plated and licorice exosomes (150 μg / mL, in terms of protein), DMXAA (12 ug / mL), and licorice exosomes encapsulating DMXAA, i.e., licorice exosomes@DMXAA (150 μg / mL, in terms of protein), were added thereto. After 2 hours, the conditioned medium was collected and cultured for 8 hours. DC cells were collected and stained with FITC-anti-mouse-CD11c; APC-anti-mouse-CD86; Brilliant Violet TM The cells were stained with 421-anti-mouse-CD80 flow cytometry antibody on ice for 15 minutes and then detected by flow cytometry. The DC cell maturation status and its statistical graphs are shown in Figure 2. Figure 4 As shown in E and F, both exosomes and DMXAA can promote the maturation of DC cells, which is manifested by the upregulation of CD80 and CD86 expression levels, and the effect of exosomes encapsulated with DMXAA on promoting the maturation of DC cells is greatly enhanced.

[0057] This example constructs a DC cell and tumor cell co-culture system and a T cell and tumor cell co-culture system. In the T cell and tumor cell co-culture system, the study found that licorice exosomes can enhance the inhibitory effect of T cells on tumor cell proliferation, and exosomes coupled with PD-L1 antibodies can significantly enhance the killing effect of T cells on tumors and inhibit tumor cell proliferation. In the DC cell and tumor cell co-culture system, both exosomes and DMXAA have the effect of promoting DC cell maturation, and the exosomes encapsulated with DMXAA greatly enhance the effect of promoting DC cell maturation.

[0058] Example 5 In vivo targeting and anticancer effects of liquorice exosome drug delivery system

[0059] The licorice exosomes in the method for constructing the licorice exosome-coupled PD-L1 antibody drug delivery system in Example 4 were replaced with licorice exosomes encapsulating DMXAA, so as to prepare exosome-like @DMXAA-aPDL1.

[0060] 2×10 6 B16F10 cells were injected into 6-week-old male C57BL / 6 mice with subcutaneous tumors. Ten days later, CY5 dye (5uM) was injected into the tail vein to dye licorice exosomes, DMXAA, exosomes@DMXAA, and exosomes@DMXAA-aPDL1 (15mg / kg, protein amount) for 12 hours at 4℃. Six hours later, the mice were dissected, and the tumor tissues and important organs (heart, liver, spleen, lung, and kidney) were separated. The tumor targeting was studied using a small animal in vivo imaging device. Then 2×10 6 B16F10 cells were injected into 6-week-old male C57BL / 6 mice to implant subcutaneous tumors. Five days later, drugs were administered, including control, exosome-like, DMXAA, exosome-like@DMXAA, and exosome-like@DMXAA-aPDL1 (15 mg / kg, in terms of protein), once every 2 days for a total of 5 times. The tumor size was measured with a vernier caliper, and the weight of the mice was recorded. Half of the mice were euthanized the day after the last dose for flow analysis, and the other half of the mice were studied for survival until natural death or the tumor volume reached 2 cm 3 Humanely sacrificed the mice, and the survival curve was drawn. After 5 treatments, the mouse tumor tissue was obtained, and the single cell suspension was obtained by grinding and then FITC-anti-mouse-CD3; APC-anti-mouse-CD4; Brilliant Violet TM The cells were stained with 421-anti-mouse-CD8 antibody and analyzed by flow cytometry.

[0061] The results are as follows Figure 5As shown in A, in vivo imaging demonstrated that licorice exosomes conjugated with PDL1 antibodies accumulated more in the tumor, and the changes in tumor volume were as shown in Figure 5 As shown in B and C, exosome-like encapsulated DMXAA-coupled PDL1 antibody can significantly reduce tumor volume. During the treatment, the body weight of mice did not change significantly, indicating the safety of the treatment. Figure 5 D. And the survival time of mice was significantly prolonged, indicating the safety of treatment. Figure 5 E. Mouse tumor tissues were collected, single-cell suspensions were obtained by grinding, and FITC-anti-mouse-CD3, APC-anti-mouse-CD4, Brilliant Violet TM After staining with 421-anti-mouse-CD8 flow cytometry antibody on ice for 15 minutes, flow cytometry was used for detection. The results are shown in Figure 5 As shown in F and G, the exosome-like@DMXAA-aPDL1 group can significantly increase the proportion of CD8+T cells in tumor tissues, and the therapeutic effect is better than that of the exosome-like group, DMXAA group, and exosome@DMXAA group, which means that anti-tumor immunity is effectively activated.

[0062] In vivo experiments verified the tumor targeting of the licorice exosome drug delivery system. The licorice exosome drug delivery system was further applied to the subcutaneous melanoma model of mice, and it was found that it can significantly enhance the killing ability of tumor-infiltrating T cells, effectively improve survival and delay tumor progression.

Claims

1. Application of licorice exosomes in the preparation of melanoma therapeutic drugs, It is characterized in that The preparation method of licorice exosomes comprises the following steps: washing and chopping licorice, making a homogenate and filtering, gradient centrifugation separation, resuspending, passing through a 0.20-0.25 μm filter membrane and squeezing, and obtaining the exosomes; the gradient centrifugation is sequentially centrifuged at 3500-4500 rpm for 18-22 min, 9500-15000 rpm for 35-45 min, and 35000-45000 g for 55-65 min, taking the supernatant and centrifuging it at 100000-200000 g for 80-100 min, and discarding the supernatant.

2. The use according to claim 1, It is characterized in that The homogenate is prepared by mixing licorice and water in a mass ratio of 1:8-12 and then crushing the mixture.

3. The use according to claim 1, It is characterized in that The gradient centrifugation is carried out in sequence at 4000-4500 rpm for 20-22 min, 10000-15000 rpm for 40-45 min, 40000-45000 g for 60-65 min, the supernatant is centrifuged at 150000-200000 g for 90-100 min, and the supernatant is discarded.

4. The use according to claim 1, It is characterized in that The membrane extrusion is performed using a 0.20-0.22 μm filter membrane.

5. Application of licorice exosome drug-carrying products in the preparation of melanoma therapeutic drugs, It is characterized in that The licorice exosome drug-loaded product uses the licorice exosomes in the application of claim 1 as a drug carrier to encapsulate the STING signal agonist and / or the coupled PD-L1 antibody.

6. The use according to claim 5, It is characterized in that The STING signal agonist is DMXAA.

7. The use according to claim 5, It is characterized in that The PD-L1 antibody is coupled to the surface of licorice exosomes via a DSPE-PEG-NHS chain.